Skip to main content
Home

Search form

  • Home
  • About Heron
    • Company Overview
    • Grants, Sponsorships, and Charitable Giving
    • Management
    • Board of Directors
    • Compliance
    • Contact Us
    • Careers
  • Our Focus
    • Our Mission
    • Our Technologies
    • About the 505(b)(2) Regulatory Pathway
  • Product Portfolio
    • Pipeline
    • SUSTOL®
    • CINVANTI™ (HTX-019)
    • HTX-011
  • Patient/​Investigator Resources
    • About Chemotherapy-Induced Nausea and Vomiting (CINV)
    • About Pain Management
    • Clinical Trials
    • Scientific Posters and Presentations
    • Publications
  • Investor Resources
    • Investor Resources Home
    • News, Events and Presentations
      • News Releases
      • Events and Webcasts
      • Corporate Presentations
    • SEC Filings
    • Stock Information
      • Stock Quote
      • Stock Chart
    • Analyst Coverage
    • Corporate Governance
      • Board of Directors
      • Committee Composition
      • Corporate Governance Documents
    • Information Request
      • Material Request
      • E-mail Alerts
      • RSS Feeds


  • Commercial Product Now Available Learn more


Commercial Product Now Available Learn more

Developing Best-in-Class Medicine. Improving Lives.

Recent News

August 09, 2017
|
Heron Therapeutics Reports Financial Results for the Three and Six Months Ended June 30, 2017 and Recent Corporate Progress
August 09, 2017
|
Heron Therapeutics Announces Initiation of Phase 3 Program for HTX-011 in Postoperative Pain Following Successful End-of-Phase 2 Meeting with FDA
May 30, 2017
|
Heron Therapeutics to Present at the Jefferies 2017 Healthcare Conference
More News

Quick Links

Pipeline
Corporate Presentation
Scientific Posters and Presentations
  • Home
  • About Heron
  • Our Focus
  • Product Portfolio
  • Patient/​Investigator Resources
  • Investor Resources
  • Site Map
  • Terms of Use
  • Privacy Statement
  • Careers

© 2017 Heron Therapeutics, Inc. All Rights Reserved.